Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Diseases and Disorders01:23

Skin Diseases and Disorders

4.6K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.6K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

271
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
271
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.2K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.2K
Skin Cancer01:30

Skin Cancer

5.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.1K
Drug Therapy01:28

Drug Therapy

139
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
139
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

268
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
268

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Structured pre- and postoperative wound management for hidradenitis suppurativa].

Dermatologie (Heidelberg, Germany)·2026
Same author

Adjunctive optical and magnetic stimulation for venous and mixed etiology leg ulcers: protocol for the NAZARÉ multicenter randomized controlled trial.

Trials·2026
Same author

Cutaneous leukocytoclastic vasculitis as acute hemorrhagic edema in a 71-year-old patient.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Therapy with lebrikizumab for refractory peristomal irritant contact dermatitis.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

S1 Guideline on Infected Interdigital Intertrigo (also called Gram-Negative Toe Web Infection).

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

pH profiling reveals progressive wound acidification during healing and higher pH in chronic non-healing wounds: a prospective, multicenter cohort study.

Scientific reports·2026

Related Experiment Video

Updated: Nov 8, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K

[Approved systemic therapies in dermatology].

Monika Kleinhans1, Carolin Funke-Lorenz1, Joachim Dissemond2

  • 1Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|April 22, 2021
PubMed
Summary

This review outlines approved systemic therapies for 50 dermatological diseases, highlighting alternatives like Compassionate Use and Early Access Programs. It addresses challenges of off-label drug use in dermatology, emphasizing informed patient consent.

Keywords:
Compassionate Use ProgramEarly Access ProgramOff-label useOrphan diseasesReimbursement

More Related Videos

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K
Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
03:47

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application

Published on: September 27, 2024

1.2K

Related Experiment Videos

Last Updated: Nov 8, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K
Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
03:47

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application

Published on: September 27, 2024

1.2K

Area of Science:

  • Dermatology
  • Systemic Therapies
  • Pharmacology

Background:

  • The availability of systemic therapies in dermatology has significantly increased.
  • Off-label use of dermatological drugs can create reimbursement issues.
  • This article provides an overview of approved systemic treatments and alternatives.

Purpose of the Study:

  • To present an overview of currently approved systemic therapies in dermatology.
  • To identify and discuss alternatives such as Compassionate Use and Early Access Programs.
  • To address challenges associated with off-label drug use in dermatological practice.

Main Methods:

  • Searched the German Federal Institute for Drugs and Medical Devices database for approved drugs.
  • Cross-referenced findings with information from the Rote Liste.
  • Compiled data on approved systemic therapies for 50 dermatologically relevant diseases.

Main Results:

  • Tabular presentation of approved systemic therapies for 50 dermatological diseases.
  • Identification of promising systemic treatment concepts supported by growing evidence.
  • Acknowledgement of the frequent lack of specific clinical studies in dermatology.

Conclusions:

  • Recent advancements offer promising systemic treatment options for dermatological conditions.
  • Off-label use, while sometimes necessary, presents practical difficulties in clinical settings.
  • Physicians must inform patients about off-label use, consider approved alternatives, and ensure adequate patient understanding.